HOXB13
Overview
HOXB13 (Homeobox B13) encodes a homeobox transcription factor expressed in the prostate and known to interact with androgen receptor signaling. Germline variants in HOXB13 — most notably G84E — are established hereditary prostate cancer susceptibility alleles. HOXB13 is enriched among presumed pathogenic germline mutations (PPGMs) in metastatic prostate cancer cohorts.
Alterations observed in the corpus
- Germline presumed pathogenic variant (PPGM) in 3/500 patients (5% of PPGM carriers) in the MET500 metastatic solid tumor cohort; identified as a non-DNA-repair prostate-cancer susceptibility allele, significantly enriched relative to ExAC controls PMID:28783718.
Cancer types (linked)
- PRAD: Germline HOXB13 pathogenic variants enriched in metastatic prostate cancer (n=3 PPGM carriers in MET500, 5% of all PPGMs); established prostate-cancer susceptibility allele PMID:28783718.
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity data reported in the corpus to date beyond its categorization as a non-DNA-repair PPGM.
Therapeutic relevance
- Germline HOXB13 carrier status has implications for genetic counseling and cascade testing; no direct targeted therapy reported in the corpus.
Open questions
- Whether germline HOXB13 variants affect response to androgen-receptor-directed therapies or PARP inhibitors in metastatic prostate cancer remains to be established.
Sources
This page was processed by entity-page-writer on 2026-05-15.